Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
about
Optimal prevention of seizures induced by high-dose busulfanAcute neurologic complications in children with systemic cancer.Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.The importance of drug interactions in epilepsy therapy.Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Busulfan in hematopoietic stem cell transplantationPharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation.Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatmentVariability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.Enzyme induction with antiepileptic drugs: cause for concern?Aspects concerning busulfan pharmacokinetics and bioavailability.Dose-dependent effects of busulfan on dog testes in preparation for spermatogonial stem cell transplantation.Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.Lorazepam for seizure prophylaxis during high-dose busulfan administration.Unusual presentation of central nervous system relapse with oculomotor nerve palsy in a case of CD56-positive acute myeloid leukemia following allogeneic stem cell transplantation.The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan.Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey.Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
P2860
Q28301571-D76EE131-B3B1-4BFE-BF22-05FF0848BAC7Q33145961-99D01C39-4847-4876-A456-4BC9C24E5CA3Q33687277-6DC49847-2518-4E54-9250-975E8F7F948EQ34123652-4BE2CD22-B972-44EA-9AF1-0F71B4535CA4Q34409335-A2FC6B69-7B59-444B-A775-189D6B91CB64Q34668052-CD920D6C-C92C-47AA-9385-74B3C943E4A4Q35053340-E963FCD1-F6F0-48EA-A3E8-90D67E335D5EQ35596516-B6AF0D5D-D576-43B9-970C-F442AFD6B5A5Q36143358-4C67FD96-46E7-4A0A-824A-B7B9E9AF6F3DQ36792760-6486D519-5358-4982-978C-51822AA733B9Q38046892-182F4FB8-ADCB-4A60-8A44-E73B4195F2F8Q41178776-6F3236D8-78BE-44EA-808D-94218045E372Q42379761-32082730-D760-44A9-8687-5045B8A1C267Q42949482-84665340-7136-44DC-9E4A-1907572E5081Q43742785-9272CB7B-2BAE-4779-BC65-C479F8C21583Q43796849-4D8417CB-5696-461E-A560-B2F9B7BC91EBQ43848123-E96506F3-29CE-4931-85BD-319AC93CB37CQ43950778-D25E5B09-9344-4254-8294-3E2D247331FCQ44050410-09A91F20-951C-445E-BB3F-E4891415AD38Q44052066-45B9C6D1-35EB-4A9B-9B4A-B52F2F9DC45AQ44383228-72C55A93-88CF-4838-9D97-50235060C06AQ44586681-E00C1F87-01C7-46F3-ACB1-49250B800B0AQ45936278-92251D4D-2480-4089-891B-54A0979D32A9Q46091045-FD308D82-3C51-4D7E-8F04-CDE7E32BC44AQ46677131-F41A4FF7-B0D5-45B8-946C-1932A4497AF4Q47116870-2791A1A0-E764-4D04-886B-1EA76E577CD3Q47308969-14060D35-80EA-49DC-B1E5-420F86268C01Q47313046-77164175-C30C-48E9-9115-CB7968052F1AQ50802622-1E038C21-DD15-4E7C-ACC1-07BC5C3DA16BQ51016254-F39513AC-6701-4E32-BF26-42FD6BDDAD7CQ52552920-6781BCEE-DE00-4689-A53F-1C13088A1B75Q53580759-79F9DB5C-137C-43A6-8600-B995008CE50B
P2860
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@en
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@nl
type
label
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@en
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@nl
prefLabel
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@en
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@nl
P2093
P2860
P356
P1476
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF00686213
P577
1993-01-01T00:00:00Z